ATE488236T1 - COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS - Google Patents

COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS

Info

Publication number
ATE488236T1
ATE488236T1 AT05796128T AT05796128T ATE488236T1 AT E488236 T1 ATE488236 T1 AT E488236T1 AT 05796128 T AT05796128 T AT 05796128T AT 05796128 T AT05796128 T AT 05796128T AT E488236 T1 ATE488236 T1 AT E488236T1
Authority
AT
Austria
Prior art keywords
compounds
dyslipidemia
treatment
lipid disorders
sequelae
Prior art date
Application number
AT05796128T
Other languages
German (de)
Inventor
James Dropinski
Guo Shi
Yong Zhang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE488236T1 publication Critical patent/ATE488236T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A class of compounds having Formula I and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of developing conditions and sequelae that are associated with these diseases, such as atherosclerosis.
AT05796128T 2004-09-16 2005-09-12 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS ATE488236T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61046604P 2004-09-16 2004-09-16
PCT/US2005/032557 WO2006033891A2 (en) 2004-09-16 2005-09-12 Compounds for the treatment of dyslipidemia and other lipid disorders

Publications (1)

Publication Number Publication Date
ATE488236T1 true ATE488236T1 (en) 2010-12-15

Family

ID=36090471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05796128T ATE488236T1 (en) 2004-09-16 2005-09-12 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS

Country Status (9)

Country Link
US (1) US7629372B2 (en)
EP (1) EP1796665B1 (en)
JP (1) JP2008513458A (en)
CN (1) CN101027056A (en)
AT (1) ATE488236T1 (en)
AU (1) AU2005287215B2 (en)
CA (1) CA2581072A1 (en)
DE (1) DE602005024836D1 (en)
WO (1) WO2006033891A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096564A1 (en) * 2005-03-04 2006-09-14 Merck & Co., Inc. Fused aromatic compounds having anti-diabetic activity
MX2008013237A (en) * 2006-04-14 2009-03-06 Merck & Co Inc Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators.
ITMI20062449A1 (en) * 2006-12-19 2008-06-20 Dipharma Spa CRYSTALLINE FORM OF RABEPRAZOLO SODICO
EP2155187B1 (en) 2007-05-07 2016-05-25 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
JP5679458B2 (en) 2009-09-28 2015-03-04 興和株式会社 Visceral fat weight reducing agent
EA024873B1 (en) 2012-09-27 2016-10-31 Кова Компани, Лтд. Therapeutic agent for dyslipidemia
KR20240152981A (en) 2013-08-28 2024-10-22 교와 가부시키가이샤 Therapeutic agent for dyslipidemia
WO2015184375A2 (en) * 2014-05-29 2015-12-03 Whitehead Institute For Biomedical Research Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2193685A1 (en) 1994-07-01 1996-01-18 Ranjan Mukherjee Screening for nuc inhibitors
DE69723680T9 (en) 1996-02-02 2004-11-04 Merck & Co., Inc. ANTIDIABETIC AGENTS
EP1011651B1 (en) 1996-02-02 2005-04-27 Merck & Co., Inc. Method of treating diabetes and related disease states
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
ES2217392T3 (en) 1996-02-02 2004-11-01 MERCK & CO., INC. ANTIDIABETIC AGENTS.
ATE236137T1 (en) * 1996-02-02 2003-04-15 Merck & Co Inc HETEROCYCLIC COMPOUNDS AS ANTIDIABETIC AGENTS AND FOR THE TREATMENT OF OBESITY
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1259494A4 (en) * 2000-02-18 2004-09-15 Merck & Co Inc ARYLOXY ACETIC ACIDS FOR DIABETES AND LIPID DISEASES
CA2427610A1 (en) * 2000-10-31 2002-08-08 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP2004537525A (en) 2001-06-11 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド Treatment of inflammatory diseases by administration of PPARδ agonist
WO2004011448A1 (en) 2002-07-25 2004-02-05 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions

Also Published As

Publication number Publication date
US20080039514A1 (en) 2008-02-14
JP2008513458A (en) 2008-05-01
CA2581072A1 (en) 2006-03-30
WO2006033891A3 (en) 2007-02-01
US7629372B2 (en) 2009-12-08
AU2005287215B2 (en) 2011-04-07
EP1796665A2 (en) 2007-06-20
EP1796665A4 (en) 2009-08-12
EP1796665B1 (en) 2010-11-17
CN101027056A (en) 2007-08-29
AU2005287215A1 (en) 2006-03-30
DE602005024836D1 (en) 2010-12-30
WO2006033891A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
DE60322075D1 (en) PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
AU2013311573A8 (en) Methods of treating Alzheimer's disease and pharmaceutical compositions thereof
ATE390925T1 (en) USE OF SUBSTITUTED QUINOLINE DERIVATIVES FOR THE TREATMENT OF DRUG RESISTANT MYCOBACTERIAL DISEASES
DE60332738D1 (en) PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
CY1116754T1 (en) NITROCATECHOL PRODUCTS AS COMT INHIBITORS
UA100132C2 (en) Isoxazolo-pyridine derivatives
ATE501721T1 (en) QUINOLINE DERIVATIVES FOR THE TREATMENT OF LATENT TUBERCULOSIS
SE0401342D0 (en) Therapeutic compounds
DE60315479D1 (en) PYRIMIDINAMIDE DERIVATIVES AND THEIR USE
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
ATE447551T1 (en) BIPHENYLOXYACETIC ACID - DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
ATE432281T1 (en) PYRROLOTRIAZINE KINASE INHIBITORS
CY1116234T1 (en) Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2 / 3 conformers
CY1114760T1 (en) Atherosclerosis Therapeutic Treatment
EA200701356A1 (en) GLYCINE TRANSPORT INHIBITORS
DE602005024836D1 (en) COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
DE602006010738D1 (en) PYRROLOÄ2,3-CÜPYRIDINDERIVATE
DK1853232T3 (en) Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods of their use
DE602005015697D1 (en) TE FOR THE TREATMENT OF ALZHEIMER DISEASE
BG105984A (en) Osanetant in the treatment of mood disorders
EA200701813A1 (en) NEW AMIDO-SUBSTITUTED 6-PHENYLPHENANTHRIDINES
ATE482707T1 (en) 1-Ä2H-1-BENZOPYRAN-2-ON-8-YLÜ-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN
DE602004010186D1 (en) DIAZASPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF GLYCINTRANSPORTER 1 AND GLYCINTRANSPORTER 2
ATE446757T1 (en) 1-Ä2H-1-BENZOPYRAN-2-ONE-8-YLÜ-PIPERAZINE DERIVATIVE FOR THE TREATMENT OF MOVEMENT DISORDERS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties